Pharmaceuticals News

ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM populationFirst Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an...

WOBURN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S.-based biopharmaceutical company engaging in the development, manufacturing,...

MediPharm Labs will release its third quarter 2026 financial results, before markets open on Thursday, November 12th,

Selskabsmeddelelse 23/2026                                         6 september 2026                              Ledende medarbejder transaktion: Se venligst vedlagte. Vedhæftede filer ...

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership Expanded with Appointment of Senior...

CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

MALVERN, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...

PORTLAND, Maine, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets...